

Overall, this editorial entitled HD-MTX and zanubrutinib combination therapy in PCNSL is well-written and contains useful information. The discussion of the the topic was well done and well-founded. The bibliography is pertinent and current. Minor modifications have been suggested. I would suggest the authors include the following topic and references in the abstract:

Primary central nervous system lymphoma (PCNSL) is an unusual form of extranodal non-Hodgkin lymphoma that may affect the brain, leptomeninges, spinal cord or eyes, representing 3% of all intracranial neoplasms Ferreri AJM. Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents. Hematology Am Soc Hematol Educ Program. 2017;2017:565-577.

Makhdoomi R. Primary CNS lymphoma in immunocompetent: a review of literature and our experience from Kashmir. Turk Neurosurg. 2011;21(1):39-47. Beraldo GL. Primary infratentorial diffuse large B-cell lymphoma: a challenging diagnosis in an immunocompetent patient. Rev Assoc Med Bras (1992). 2019 Feb;65(2):136-140.

I thank the reviewer for their suggestions.

I have cited the references suggested by the reviewer in the manuscript and highlighted them in yellow.